NabGen raised $3 million to develop a universal antibody suppressant that blocks AAV-neutralizing and anti-drug antibodies, enabling clinicians to improve gene therapy delivery and treat rare autoimmune and transplant-related conditions.
NabGen raised $3 million to develop a universal antibody suppressant that blocks AAV-neutralizing and anti-drug antibodies, enabling clinicians to improve gene therapy delivery and treat rare autoimmune and transplant-related conditions.
